Multivariate analysis of febrile neutropenia occurrence in patients with non‐Hodgkin lymphoma: data from the INC‐EU Prospective Observational European Neutropenia Study
Open Access
- 27 January 2009
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 144 (5), 677-685
- https://doi.org/10.1111/j.1365-2141.2008.07514.x
Abstract
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy. Identifying patients most at risk of developing FN might help physicians to target prophylactic treatment with colony-stimulating factor (CSF), in order to decrease the incidence, or duration, of myelosuppression and facilitate delivery of chemotherapy as planned. We present a risk model for FN occurrence in the first cycle of chemotherapy, based on a subgroup of 240 patients with non-Hodgkin lymphoma (NHL) enroled in our European prospective observational study. Eligible patients had an International Prognostic Index of 0–3, and were scheduled to receive a new myelosuppressive chemotherapy regimen with at least four cycles. Clinically relevant factors significantly associated with cycle 1 FN were older age, increasing planned cyclophosphamide dose, a history of previous chemotherapy, a history of recent infection, and low baseline albumin (<35 g/l). Prophylactic CSF use and higher weight were associated with a significant protective effect. The model had high sensitivity (81%) and specificity (80%). Our model, together with treatment guidelines, may rationalise the clinical decision of whether to support patients with CSF primary prophylaxis based on their risk factor profile. Further validation is required.Keywords
This publication has 35 references indexed in Scilit:
- Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOPAnnals of Hematology, 2007
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal Of Cancer, 2006
- Risk assessment model for haematologic toxicity (HT) in patients with solid tumours (ST) during the first chemotherapy (CT) cycleJournal of Clinical Oncology, 2006
- Chemotherapy‐induced neutropeniaCancer, 2004
- Myelotoxicity and Dose Intensity of Chemotherapy: Reporting Practices From Randomized Clinical TrialsJournal of the National Comprehensive Cancer Network, 2003
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Dose and Dose Intensity as Determinants of Outcome in the Adjuvant Treatment of Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Note on Free Lunches and Cross-ValidationNeural Computation, 1997
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993